These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 11977556)

  • 21. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
    Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
    Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.
    Chang HR
    Cancer; 2010 Jun; 116(12):2856-67. PubMed ID: 20564392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.
    Prescrire Int; 2006 Feb; 15(81):3-5. PubMed ID: 16548094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
    Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
    Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.
    Janku F; Pribylova O; Zimovjanova M; Pazdrova G; Safanda M; Zemanova M; Petruzelka L
    Bull Cancer; 2004 Oct; 91(10):E279-83. PubMed ID: 15582895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer.
    Leonard DS; Hill AD; Kelly L; Dijkstra B; McDermott E; O'Higgins NJ
    Br J Surg; 2002 Mar; 89(3):262-71. PubMed ID: 11872048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ongoing and planned adjuvant trials with trastuzumab.
    Perez EA; Hortobagyi GN
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):26-32; discussion 92-100. PubMed ID: 11236024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Herceptin-based therapy for breast cancer].
    Tokuda Y; Saito Y; Suzuki Y
    Nihon Rinsho; 2006 Mar; 64(3):540-5. PubMed ID: 16529047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.
    Pegram MD; Slamon DJ
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):89-95. PubMed ID: 10482199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Use of trastuzumab in the therapy of breast cancer].
    Riemer AB; Zielinski CC
    Ther Umsch; 2008 Apr; 65(4):217-22. PubMed ID: 18622914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
    Bengala C; Zamagni C; Pedrazzoli P; Matteucci P; Ballestrero A; Da Prada G; Martino M; Rosti G; Danova M; Bregni M; Jovic G; Guarneri V; Maur M; Conte PF;
    Br J Cancer; 2006 Apr; 94(7):1016-20. PubMed ID: 16570045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
    Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
    J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
    Cortes J; Di Cosimo S; Climent MA; Cortés-Funes H; Lluch A; Gascón P; Mayordomo JI; Gil M; Benavides M; Cirera L; Ojeda B; Rodríguez CA; Trigo JM; Vazquez J; Regueiro P; Dorado JF; Baselga J;
    Clin Cancer Res; 2009 Jan; 15(1):307-14. PubMed ID: 19118059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical trials of single-agent trastuzumab (Herceptin).
    Baselga J
    Semin Oncol; 2000 Oct; 27(5 Suppl 9):20-6. PubMed ID: 11049053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What's so special about [symbol: see text] trastuzumab?
    Drug Ther Bull; 2002 Sep; 40(9):65-7. PubMed ID: 12298222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.